As with previous funds, TVM LSV VI is a life science investment fund with a strong emphasis on drug discovery and development and companies through all development stages – from early discovery stage to pure growth capital in profitable companies - in Europe and the U.S. The fund had its first IPO in June 2006 with the listing of BioXell in Switzerland and its second IPO with Newron, also in Switzerland.
